MapLight Therapeutics, Inc.
47.90%
20,906,689
1770069
Jul 29, 2026
Aug 3, 2026, 09:00 PM
Reporting Persons (4)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Catalyst4, Inc. | CO | 47.90% | 20,906,689 | 20,906,689 | 0 |
| Robert Brown | Individual | 47.90% | 20,906,689 | 0 | 20,906,689 |
| Ekemini Riley | Individual | 47.90% | 20,906,689 | 0 | 20,906,689 |
| Mark Vorsatz | Individual | 47.90% | 20,906,689 | 0 | 20,906,689 |
Disclosure Items (4)
Common Stock, $0.0001 par value per share
MapLight Therapeutics, Inc.
800 Chesapeake Drive, Redwood City, CA, 94063
Item 3 of the Schedule 13D is hereby amended and supplemented by adding the following information: During the last 60 days, the Reporting Persons acquired 1,209,225 Shares of the Issuer in multiple open market transactions for an aggregate purchase price of approximately $15.3 million, including commissions, as further disclosed in Item 5(c) of this Schedule 13D, which is incorporated by reference herein. The source of funds for the purchase of such Shares of the Issuer was the working capital of Catalyst. No part of the purchase price was represented by borrowed funds or other consideration obtained for the purpose of acquiring, holding, trading, or voting the securities, and there were no loans or financing arrangements involved in the transaction, with no other parties providing funds or consideration.
Item 5(c) of the Schedule 13D is hereby amended and supplemented by adding the following information: The transactions by the Reporting Persons in the Shares of the Issuer during the past 60 days are set forth in Annex A to this Schedule 13D. This Amendment is being filed because the additional purchases effected by the Reporting Person subsequent to the Schedule 13D filed by the Reporting Person on November 20, 2025 (the "Prior Filing"), represent a material increase to the Reporting Person's ownership percentage of the Issuer's outstanding Shares. The transactions set forth in Annex A include the additional purchases of Shares effected by Catalyst subsequent to the Prior Filing, which are identified in Annex A. The Reporting Persons note that such additional purchases were previously disclosed on a Form 4 filed by Catalyst with the Securities and Exchange Commission on July 30, 2026. Except as otherwise disclosed herein, the Reporting Persons have not effected any transaction in the Shares in the last 60 days.
Annex A: Schedule of Transactions